IRLAB Therapeutics (IRLAB) Q1 2025 earnings summary

Executive summary

• Achieved regulatory alignment with EMA and FDA for Phase III mesdopetam, focusing on adult Parkinson's patients with levodopa-induced dyskinesias.

• Advanced pipeline with significant progress in mesdopetam, pirepemat, and IRL757 clinical programs, including positive clinical results for pirepemat and IRL757.

• Deepened strategic partnerships, notably with MSRD/Otsuka and the Michael J. Fox Foundation, securing full funding for IRL757's next clinical phase.

• Expanded patent protection for mesdopetam and pirepemat, extending exclusivity into the 2040s.

Financial highlights

• Cash and cash equivalents increased to SEK 88.6 million from SEK 73.1 million year-over-year, aided by new loans and milestone payments.

• Net sales for Q1–Q4 2024 were SEK 4.4 million, down sharply from SEK 94.6 million in Q1 2024.

• Operating loss narrowed to SEK -28.6 million from SEK -37.6 million year-over-year.

• Earnings per share improved to SEK -0.65 from SEK -0.75 year-over-year.

• Cash flow from operating activities was SEK 6.3 million, up from SEK -38.2 million year-over-year.

Outlook and guidance

• Preparing for registration-enabling Phase III studies for mesdopetam, with design agreed by both FDA and EMA.

• IRL757 patient study in Parkinson's apathy to begin in H2 2025, fully funded by MSRD/Otsuka.

• Pirepemat strategy being defined following Phase IIb data; further analyses and next steps planned.

• IRL942 and IRL1117 preclinical programs progressing, but IRL942's pace slowed to prioritize key projects.